Valuation: Shield Therapeutics plc

Market Cap 4.22Cr 5.68Cr 4.94Cr 4.6Cr 7.97Cr 542.3Cr 8.09Cr 54Cr 21Cr 269.98Cr 21Cr 21Cr 905.3Cr P/E 2026 *
-180x
P/E 2027 * 5.35x
Enterprise Value 6.05Cr 8.15Cr 7.08Cr 6.59Cr 11Cr 777.74Cr 12Cr 78Cr 30Cr 387.19Cr 31Cr 30Cr 1.3TCr EV / Sales 2026 *
1.08x
EV / Sales 2027 * 0.7x
Free-Float
38.23%
Yield 2026 *
-
Yield 2027 * -
1 day-10.23%
1 week-35.77%
1 month-35.77%
3 months-50.00%
6 months-63.26%
Current year-59.90%
1 week 3.8
Extreme 3.802
6.3
1 month 3.8
Extreme 3.802
6.5
Current year 3.8
Extreme 3.802
12.5
1 year 3.8
Extreme 3.802
12.5
3 years 1.06
Extreme 1.0625
12.85
5 years 1.06
Extreme 1.0625
53
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 24/07/2024
Investor Relations Contact - -
General Counsel - 01/01/2026
Director TitleAgeSince
Director/Board Member 68 01/02/2016
Chairman 70 18/06/2020
Director/Board Member 59 26/06/2020
Date Insider Type Main position Quantity % Market Cap.
14/10/25 Free

Chief Executive Officer

15,47,262 0.1485%
13/02/25 Free

Chief Executive Officer

50,00,000 0.4800%
13/02/25 Buy

Chief Executive Officer

5,75,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
-10.23%-35.77%-12.22%-63.26% 5.68Cr
+3.29%+16.25%+36.46%+3.19% 7.62TCr
+2.72%-9.39%+20.58%+172.43% 4.89TCr
-2.75%+48.50%+48.50%+48.50% 4.78TCr
-3.81%+7.74%-53.40%-54.31% 4.14TCr
-2.40%+0.38%+53.81%-24.64% 3TCr
-2.82%+1.57%+58.12%+87.66% 2.42TCr
-5.35%+1.39%+98.59%-51.89% 2.19TCr
-1.59%-3.61%-6.77%+150.58% 1.92TCr
-0.42%+2.89%+77.99%+128.67% 1.71TCr
Average -2.34%-2.24%+32.17%+39.69% 3.27TCr
Weighted average by Cap. -0.62%+2.97%+31.45%+43.13%

Financials

2026 *2027 *
Net sales 5.63Cr 7.58Cr 6.59Cr 6.13Cr 11Cr 723.19Cr 11Cr 72Cr 28Cr 360.04Cr 28Cr 28Cr 1.21TCr 7.59Cr 10Cr 8.88Cr 8.26Cr 14Cr 974.78Cr 15Cr 97Cr 38Cr 485.29Cr 38Cr 38Cr 1.63TCr
Net income -71T -95.57T -83.08T -77.33T -1L -91.24L -1L -9L -4L -45.42L -4L -4L -1.52Cr 78.59L 1.06Cr 91.96L 85.6L 1.48Cr 100.99Cr 1.51Cr 10Cr 3.96Cr 50Cr 3.97Cr 3.89Cr 168.59Cr
Net Debt 1.83Cr 2.47Cr 2.14Cr 2Cr 3.46Cr 235.44Cr 3.51Cr 24Cr 9.23Cr 117.21Cr 9.26Cr 9.06Cr 393.03Cr 1.11Cr 1.5Cr 1.3Cr 1.21Cr 2.1Cr 143.05Cr 2.13Cr 14Cr 5.61Cr 71Cr 5.63Cr 5.5Cr 238.81Cr
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
31/26/31 GBX 3.950 -10.23% 1,70,94,740
30/26/30 GBX 4.400 -23.48% 2,45,08,381
29/26/29 GBX 5.750 -0.86% 16,22,161
28/26/28 GBX 5.800 +1.75% 14,16,955
27/26/27 GBX 5.700 -7.32% 37,81,616
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0395GBP
Average target price
0.1667GBP
Spread / Average Target
+321.95%

Annual profits - Rate of surprise